ACC/AHA/HFSA Heart Failure Guidelines and Putting Them Into Practice

Published: 17 April 2022

  • Views:

    Views Icon 8926
  • Likes:

    Heart Icon 0


Full programme


The new 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure were presented at the recent ACC Scientific sessions.


In this series of short peer-to-peer discussions, Dr Mikhail Kosiborod, Dr Biykem Bozkurt, and Prof Giuseppe Rosano, discuss the main updates.

This activity was funded via an unrestricted educational grant from AstraZeneca.

Learning Objectives

Following the completion of this programme, physicians will be in a position to:

  • Summarise the main updates to the 2022 ACC heart failure guidelines
  • Discuss data available on the use of SGLT2 inhibitors both in the treatment of HFpEF and across the Heart Failure spectrum
  • Recall how heart failure practice is likely to change in the months ahead

Target Audience

  • Global Cardiologists
  • Heart Failure Specialists
  • Primary Care Physicians
  • Nurses
  • Pharmacists
  • Other allied HCPs

Series overview

Part 1

Guideline Directed Medical Therapy in HF

Part 2

SGLT-2 Inhibitors Across the Range Of EF

Part 3

Using Guideline Directed Medical Therapy to Improve Outcomes

Faculty Biographies

Biykem  Bozkurt

Biykem Bozkurt

Dr Biykem Bozkurt is the Immediate Past President of the Heart Failure Society of America. 

Dr Bozkurt is a Professor of Medicine, an advanced heart failure and cardiac transplantation specialist, Medical Care Line Executive (Medicine Department Chair) at the DeBakey VA Medical Center; W.A. “Tex” and Deborah Moncrief, Jr., Chair; Mary and Gordon Cain Chair; Vice-Chair of Department of Medicine; Director of the Winters Center for Heart Failure and Associate Director of Cardiovascular Research Institute at Baylor College of Medicine. 

View full profile
Giuseppe Rosano

Giuseppe Rosano

Consultant Cardiologist and Professor of Cardiology (Hon)

Giuseppe Rosano is Consultant Cardiologist and Professor of Cardiology at St George’s, University of London where he is also the director of MSc Heart Failure.

After obtaining his MD in Medicine and Surgery at the La Sapienza University of Rome, Prof Rosano obtained his specialisation in cardiology from the same University before attaining his PhD in Medical Sciences from Imperial College London. His research interests focus on experimental and clinical pharmacology, heart failure, cardiac metabolism, diabetes and gender differences in cardiovascular diseases.

View full profile
Mikhail Kosiborod

Mikhail Kosiborod


Dr Mikhail Kosiborod is a cardiologist who serves as Vice President of Research at Saint Luke's Health System, and Professor of Medicine at the University of Missouri-Kansas City, US.

He is also Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute. Dr Kosiborod is an internationally-recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes.

Dr Kosiborod is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.

View full profile